How do you choose between finerenone and traditional steroidal MRAs for patients with heart failure and mildly reduced or preserved EF, considering recent results showing finerenone's efficacy in reducing heart failure events?

How do you choose between finerenone and traditional steroidal MRAs for patients with heart failure and mildly reduced or preserved EF, given recent results showing finerenone's efficacy in reducing heart failure events?

• I prefer finerenone due to its demonstrated efficacy in reducing heart failure events and its potentially favorable side effect profile
• I primarily use traditional steroidal MRAs because of my familiarity with them and their long-established use in heart failure management
• Insurance coverage or cost issues often dictate whether I use finerenone or traditional steroidal MRAs
• Other